Phosphorylated Tau 181 Serum Levels Predict Alzheimer's Disease in the Preclinical Stage.

ABSTRACT:

Background

There is an urgent need for cost-effective, easy-to-measure biomarkers to identify subjects who will develop Alzheimer's disease (AD), especially at the pre-symptomatic stage. This stage can be determined in autosomal dominant AD (ADAD) which offers the opportunity to observe the dynamic biomarker changes during the life-course of AD stages. This study aimed to investigate serum biomarkers during different AD stages and potential novel protein biomarkers of presymptomatic AD.

Methods

In the first stage, 32 individuals [20 mutation carriers including 10 with AD, and 10 with mild cognitive impairment (MCI), and 12 healthy controls] from ADAD families were analyzed. All subjects underwent a complete clinical evaluation and a comprehensive neuropsychological battery.

SUBMITTER: Qin W 

PROVIDER: S-EPMC9234327 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature